AI-generated summary
The authors studied how porfimer sodium, a photodynamic therapy agent, is processed in the body, comparing 24 healthy volunteers (12 men and 12 women) and five male patients with oesophageal cancer. They report no meaningful sex-related difference in key pharmacokinetic measures, and cancer patients had broadly comparable values, though their terminal elimination half-life was shorter. The study was small, and the authors' conclusions about sex-specific labelling and timing rely on these modest sample sizes.
- Who or what was studied
- 24 healthy volunteers (12 men and 12 women) and 5 male patients with oesophageal cancer undergoing palliative photodynamic therapy
- Limits stated in the abstract
- The study enrolled a small number of participants, including only five cancer patients, and used a sparse blood sampling schedule that the authors say may explain the time-to-maximum-concentration difference between sexes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, GRADE, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.